Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

M. Brueckmann · SciRah

Researcher profile · Semantic Scholar

M. Brueckmann

Share profile

M. Brueckmann — researcher profile on SciRah

h-index: 64
Works: 240
Citations: 25K

Most-cited papers

Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
M. Packer, S. Anker, J. Butler, G. Filippatos +35 more
2020New England Journal of Medicine3,877 citations Open access
Semantic Scholar
Empagliflozin in Heart Failure with a Preserved Ejection Fraction.
S. Anker, J. Butler, G. Filippatos, J. Ferreira +37 more
2021New England Journal of Medicine3,302 citations Open access
Semantic Scholar
Empagliflozin in Patients with Chronic Kidney Disease
W. Herrington, N. Staplin, C. Wanner, J. B. Green +35 more
2022New England Journal of Medicine1,521 citations Open access
Semantic Scholar
SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials.
F. Zannad, J. Ferreira, S. Pocock, S. Anker +7 more
2020The Lancet1,111 citations Open access
Semantic Scholar
The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial
A. Voors, C. Angermann, J. Teerlink, S. Collins +26 more
2022Nature Medicine775 citations Open access
Semantic Scholar
Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source
H. Diener, R. Sacco, D. Easton, C. Granger +21 more
2019New England Journal of Medicine638 citations Open access
Semantic Scholar
Impact of Diabetes on The Effects Of Sodium Glucose Co-Transporter-2 (SGLT2) Inhibitors on Kidney Outcomes: Collaborative Meta-Analysis of Large Placebo-Controlled Trials
C. Baigent, J. Emberson, R. Haynes, W. Herrington +34 more
2022The Lancet576 citations Open access
Semantic Scholar
Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status
S. Anker, J. Butler, G. Filippatos, M. Khan +16 more
2020Circulation265 citations Open access
Semantic Scholar
Evaluation of the effects of sodium–glucose co‐transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR‐Preserved Trial
S. Anker, J. Butler, G. Filippatos, Waheed Jamal +8 more
2019European Journal of Heart Failure218 citations Open access
Semantic Scholar
Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction
M. Packer, S. Anker, J. Butler, G. Filippatos +15 more
2020Circulation210 citations Open access
Semantic Scholar
Impact of empagliflozin on decongestion in acute heart failure: the EMPULSE trial
J. Biegus, A. Voors, S. Collins, M. Kosiborod +10 more
2022European Heart Journal208 citations Open access
Semantic Scholar
Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes.
W. Abraham, J. Lindenfeld, P. Ponikowski, P. Agostoni +23 more
2020European Heart Journal182 citations
Semantic Scholar
Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial
J. Butler, S. Anker, G. Filippatos, M. Khan +16 more
2021European Heart Journal162 citations Open access
Semantic Scholar
Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function
F. Zannad, J. Ferreira, S. Pocock, C. Zeller +9 more
2020Circulation161 citations Open access
Semantic Scholar
Evaluation of the effect of sodium–glucose co‐transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR‐Reduced trial
M. Packer, J. Butler, G. Filippatos, Waheed Jamal +8 more
2019European Journal of Heart Failure156 citations Open access
Semantic Scholar
Empagliflozin, Health Status, and Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The EMPEROR-Preserved Trial
J. Butler, G. Filippatos, Tariq Jamal Siddiqi, M. Brueckmann +16 more
2021Circulation154 citations Open access
Semantic Scholar
Empagliflozin in Patients With Heart Failure, Reduced Ejection Fraction, and Volume Overload: EMPEROR-Reduced Trial.
M. Packer, S. Anker, J. Butler, G. Filippatos +8 more
2021Journal of the American College of Cardiology147 citations Open access
Semantic Scholar
Interplay of Mineralocorticoid Receptor Antagonists and Empagliflozin in Heart Failure: EMPEROR-Reduced.
J. Ferreira, F. Zannad, S. Pocock, S. Anker +7 more
2021Journal of the American College of Cardiology141 citations Open access
Semantic Scholar
Dabigatran etexilate for the treatment of acute venous thromboembolism in children (DIVERSITY): a randomised, controlled, open-label, phase 2b/3, non-inferiority trial.
J. Halton, L. Brandão, M. Luciani, L. Bomgaars +82 more
2020The Lancet Haematology124 citations
Semantic Scholar
Uric acid and sodium-glucose cotransporter-2 inhibition with empagliflozin in heart failure with reduced ejection fraction: the EMPEROR-reduced trial
W. Doehner, S. Anker, J. Butler, F. Zannad +8 more
2022European Heart Journal113 citations Open access
Semantic Scholar
Effects of Empagliflozin on Symptoms, Physical Limitations, and Quality of Life in Patients Hospitalized for Acute Heart Failure: Results From the EMPULSE Trial
M. Kosiborod, C. Angermann, S. Collins, J. Teerlink +12 more
2022Circulation110 citations Open access
Semantic Scholar
Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR‐Preserved trial
S. Anker, J. Butler, G. Filippatos, Muhammad Shahzeb Khan +34 more
2020European Journal of Heart Failure110 citations Open access
Semantic Scholar
Influence of neprilysin inhibition on the efficacy and safety of empagliflozin in patients with chronic heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial
M. Packer, S. Anker, J. Butler, G. Filippatos +12 more
2021European Heart Journal109 citations Open access
Semantic Scholar
Efficacy of empagliflozin on heart failure and renal outcomes in patients with atrial fibrillation: data from the EMPA‐REG OUTCOME trial
M. Böhm, J. Slawik, M. Brueckmann, M. Mattheus +9 more
2019European Journal of Heart Failure98 citations Open access
Semantic Scholar
Safety of dabigatran etexilate for the secondary prevention of venous thromboembolism in children.
L. Brandão, M. Albisetti, J. Halton, L. Bomgaars +14 more
2019Blood85 citations Open access
Semantic Scholar
Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: a subgroup analysis from the RE-DUAL PCI trial
J. Oldgren, P. Steg, S. Hohnloser, G. Lip +7 more
2019European Heart Journal84 citations Open access
Semantic Scholar
Sodium–glucose co‐transporter 2 inhibition in patients hospitalized for acute decompensated heart failure: rationale for and design of the EMPULSE trial
J. Tromp, P. Ponikowski, Afshin Salsali, C. Angermann +11 more
2021European Journal of Heart Failure83 citations Open access
Semantic Scholar
Empagliflozin for Heart Failure With Preserved Left Ventricular Ejection Fraction With and Without Diabetes
G. Filippatos, J. Butler, D. Farmakis, F. Zannad +9 more
2022Circulation82 citations Open access
Semantic Scholar
Empagliflozin and Major Renal Outcomes in Heart Failure.
M. Packer, J. Butler, F. Zannad, S. Pocock +7 more
2021New England Journal of Medicine78 citations Open access
Semantic Scholar
Concomitant Oral Anticoagulant and Nonsteroidal Anti-Inflammatory Drug Therapy in Patients With Atrial Fibrillation.
A. Kent, M. Brueckmann, Mandy Fraessdorf, S. Connolly +6 more
2018Journal of the American College of Cardiology73 citations Open access
Semantic Scholar
Empagliflozin Improves Cardiovascular and Renal Outcomes in Heart Failure Irrespective of Systolic Blood Pressure.
M. Böhm, S. Anker, J. Butler, G. Filippatos +11 more
2021Journal of the American College of Cardiology68 citations Open access
Semantic Scholar
Empagliflozin Improves Outcomes in Patients With Heart Failure and Preserved Ejection Fraction Irrespective of Age.
M. Böhm, J. Butler, G. Filippatos, J. Ferreira +11 more
2022Journal of the American College of Cardiology66 citations Open access
Semantic Scholar
Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction
J. Butler, M. Packer, G. Filippatos, J. Ferreira +6 more
2021European Heart Journal64 citations Open access
Semantic Scholar
Blinded Withdrawal of Long-Term Randomized Treatment With Empagliflozin or Placebo in Patients With Heart Failure
M. Packer, J. Butler, C. Zeller, S. Pocock +6 more
2023Circulation61 citations Open access
Semantic Scholar
Empagliflozin Is Associated With a Lower Risk of Post-Acute Heart Failure Rehospitalization and Mortality.
G. Savarese, N. Sattar, J. Januzzi, S. Verma +10 more
2019Circulation53 citations Open access
Semantic Scholar
Novel biomarker-driven prognostic models to predict morbidity and mortality in chronic heart failure: the EMPEROR-Reduced trial
S. Pocock, J. Ferreira, J. Gregson, S. Anker +9 more
2021European Heart Journal52 citations Open access
Semantic Scholar
Effects of empagliflozin on cardiovascular and renal outcomes in heart failure with reduced ejection fraction according to age: a secondary analysis of EMPEROR‐Reduced
G. Filippatos, S. Anker, J. Butler, D. Farmakis +7 more
2022European Journal of Heart Failure50 citations Open access
Semantic Scholar
Regional and ethnic influences on the response to empagliflozin in patients with heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial
C. Lam, J. Ferreira, E. Pfarr, David Sim +12 more
2021European Heart Journal49 citations Open access
Semantic Scholar
Effects of Empagliflozin in Women and Men With Heart Failure and Preserved Ejection Fraction
J. Butler, G. Filippatos, T. Siddiqi, J. Ferreira +20 more
2022Circulation47 citations Open access
Semantic Scholar
Renal effects of empagliflozin in patients hospitalized for acute heart failure: from the EMPULSE trial
A. Voors, K. Damman, J. Teerlink, C. Angermann +11 more
2022European Journal of Heart Failure46 citations Open access
Semantic Scholar
Association of Empagliflozin Treatment With Albuminuria Levels in Patients With Heart Failure
J. Ferreira, F. Zannad, J. Butler, G. Filippatos +6 more
2022JAMA cardiology46 citations Open access
Semantic Scholar
Comorbidities and cause-specific outcomes in heart failure across the ejection fraction spectrum: A blueprint for clinical trial design.
G. Savarese, C. Settergren, Benedikt Schrage, T. Thorvaldsen +12 more
2020International Journal of Cardiology45 citations Open access
Semantic Scholar
Empagliflozin in heart failure with preserved ejection fraction with and without atrial fibrillation
G. Filippatos, D. Farmakis, J. Butler, F. Zannad +7 more
2023European Journal of Heart Failure43 citations Open access
Semantic Scholar
Empagliflozin Improves Kidney Outcomes in Patients With or Without Heart Failure.
J. Butler, F. Zannad, D. Fitchett, B. Zinman +7 more
2019Circulation: Heart Failure43 citations
Semantic Scholar
Safety and Efficacy of Empagliflozin and Diuretic Use in Patients with Heart Failure and Preserved Ejection Fraction
J. Butler, M. Usman, G. Filippatos, J. Ferreira +13 more
2023JAMA cardiology41 citations Open access
Semantic Scholar
Concentration‐dependent clinical and prognostic importance of high‐sensitivity cardiac troponin T in heart failure and a reduced ejection fraction and the influence of empagliflozin: the EMPEROR‐Reduced trial
M. Packer, J. Januzzi, J. Ferreira, S. Anker +8 more
2021European Journal of Heart Failure40 citations Open access
Semantic Scholar
Predictors of Atrial Fibrillation Development in Patients With Embolic Stroke of Undetermined Source: An Analysis of the RE-SPECT ESUS Trial
M. Bahit, R. Sacco, J. Easton, J. Meyerhoff +11 more
2021Circulation39 citations Open access
Semantic Scholar
Empagliflozin, irrespective of blood pressure, improves outcomes in heart failure with preserved ejection fraction: the EMPEROR-Preserved trial
M. Böhm, S. Anker, F. Mahfoud, L. Lauder +10 more
2022European Heart Journal38 citations Open access
Semantic Scholar
Efficacy of Empagliflozin in Patients With Heart Failure Across Kidney Risk Categories.
J. Butler, M. Packer, T. Siddiqi, M. Böhm +11 more
2023Journal of the American College of Cardiology37 citations Open access
Semantic Scholar
Prognostic Implications of N-terminal Pro-B Type Natriuretic Peptide and High-Sensitivity Cardiac Troponin T in EMPEROR-Preserved.
J. Januzzi, J. Butler, F. Zannad, G. Filippatos +9 more
2022JACC. Heart failure37 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

M. Packer×33
Invite
M. Packer — researcher profile on SciRah
J. Butler×33
Invite
J. Butler — researcher profile on SciRah
F. Zannad×33
Invite
F. Zannad — researcher profile on SciRah
G. Filippatos×31
Invite
G. Filippatos — researcher profile on SciRah

×31

Invite

J. Ferreira — researcher profile on SciRah

Invite

S. Anker — researcher profile on SciRah

Invite

S. Pocock — researcher profile on SciRah

Waheed Jamal×16

Invite

Waheed Jamal — researcher profile on SciRah

Invite

S. Anker — researcher profile on SciRah

Invite

C. Zeller — researcher profile on SciRah

Invite

C. Wanner — researcher profile on SciRah

Invite

S. Pocock — researcher profile on SciRah